NCT02349139 - Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 19, 2015

Primary Completion Date

July 14, 2017

Study Completion Date

August 17, 2017

Conditions

Cancer of the ProstateNeoplasms, ProstateProstate CancerProstatic CancerNeoplasms, ProstaticProstate Neoplasms, Castration-resistant

Interventions

DRUG

ASN001: Escalating dose Part A

Androgen inhibitor

Trial Locations (6)

Abramson Cancer Center, Hospital of the Univ. of Pennsylvania, Philadelphia

University of Virginia Cancer Center, Charlottesville

Cleveland Clinic Foundation, Cleveland

Karmanos Cancer Institute, Detroit

South Texas Accelerated Research Therapeutics, San Antonio

UCLA Medical Center, Clark Urology Center, Los Angeles